ACADIA Pharmaceuticals Inc. ( (ACAD) ) has released its Q3 earnings. Here is a breakdown of the information ACADIA Pharmaceuticals Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Acadia Pharmaceuticals Inc. is a biotechnology company focused on developing innovative treatments for neurological and rare diseases, with a portfolio that includes FDA-approved therapies for Parkinson’s disease psychosis and Rett syndrome.
In its third-quarter 2025 financial report, Acadia Pharmaceuticals announced a total revenue of $278.6 million, marking an 11% increase compared to the previous year. The company highlighted strong sales performances from its key products, NUPLAZID and DAYBUE, and expressed confidence in surpassing $1 billion in sales for the year.
The company reported NUPLAZID net product sales of $177.5 million, a 12% increase year-over-year, driven by new prescriptions. DAYBUE sales reached $101.1 million, up 11%, supported by an expanded field force and international patient supply programs. Acadia also advanced its pipeline with new clinical trials for treatments targeting Lewy Body Dementia Psychosis and Rett syndrome.
Acadia’s net income for the quarter was $71.8 million, or $0.42 per diluted share, reflecting a significant increase from the previous year due to higher pre-tax income and a one-time tax benefit. The company ended the quarter with $847 million in cash and investments, positioning it well for future growth.
Looking ahead, Acadia Pharmaceuticals remains optimistic about its growth trajectory, with updated revenue guidance for 2025 reflecting strong product sales and strategic pipeline advancements. The company continues to focus on expanding its market presence and developing new therapeutic solutions for underserved patient communities.